Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy

Nishimura, Goshi; Komatsu, Masanori; Hata, Masaharu; Yabuki, Kenichiro; Taguchi, Takahide; Takahashi, Masahiro; Shiono, Osamu; Sano, Daisuke; Arai, Yasuhiro; Takahashi, Hideaki; Chiba, Yoshihiro

doi:10.1007/s10147-015-0890-8

Cited by 6 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a strong correlation between MLV and SUV mean (r = 0.90); this result is probably due to the few patients included in the study. Our result is consistent with observations in oncology, with some studies suggesting TLG as a better predictor of outcomes in patients with lung or cervical cancer [17, 25]. We found MLV independently associated with prognosis, like TLG, so the volume of the lung with an altered uptake may be more informative to assess prognosis than the mean SUV in this volume.…”

Section: Discussionsupporting

confidence: 92%

[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis

et al. 2017

View full text Add to dashboard Cite

BackgroundIdiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by an unpredictable course. Prognostic markers and disease activity markers are needed. The purpose of this single-center retrospective study was to evaluate the prognostic value of lung fluorodeoxyglucose ([18F]-FDG) uptake assessed by standardized uptake value (SUV), metabolic lung volume (MLV) and total lesion glycolysis (TLG) in patients with IPF.MethodsWe included 27 IPF patients (IPF group) and 15 patients with a gastrointestinal neuroendocrine tumor without thoracic involvement (control group). We quantified lung SUV mean and SUV max, MLV and TLG and assessed clinical data, high-resolution CT (HRCT) fibrosis and ground-glass score; lung function; gender, age, physiology (GAP) stage at inclusion and during follow-up; and survival.ResultsLung SUV mean and SUV max were higher in IPF patients than controls (p <0.00001). For patients with IPF, SUV mean, SUV max, MLV and TLG were correlated with severity of lung involvement as measured by a decline in forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) and increased GAP score. In a univariate and in a multivariate Cox proportional-hazards model, risk of death was increased although not significantly with high SUV mean. On univariate analysis, risk of death was significantly associated with high TLG and MLV, which disappeared after adjustment functional variables or GAP index. Increased MLV and TLG were independent predictors of death or disease progression during the 12 months after PET scan completion (for every 100-point increase in TLG, hazard ratio [HR]: 1.11 (95% CI 1.06; 1.36), p = 0.003; for every 100-point increase in MLV, HR: 1.20 (1.04; 1.19), p = 0.002). On multivariable analysis including TLG or MLV with age, FVC, and DLCO or GAP index, TLG and MLV remained associated with progression-free survival (HR: 1.1 [1.03; 1.22], p = 0.01; and 1.13 [1.0; 1.2], p = 0.005).ConclusionFDG lung uptake may be a marker of IPF severity and predict progression-free survival for patients with IPF.

show abstract

Section: Discussionsupporting

confidence: 92%

[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefore, the concept of metabolic tumor burden, such as MTV and TLG, has been introduced to consider both FDG uptake and tumor volume. In this study, MTV 2.5 and TLG 2.5 differed significantly with respect to PFS and OS, like the results of previous studies . In addition, we examined whether the changing rate of MTV and TLG, which were not used in those studies, can predict patient survival.…”

Section: Discussionsupporting

confidence: 56%

“…Cervical lymph node metastases were defined using the criteria reported by Nakamura et al The maximum standardized uptake value (SUV max ), MTV, and TLG were calculated for all lesions for both the early and delayed phases. The cutoff SUVs for calculating MTV and TLG were defined as 2.5% and 40% of the SUV max , respectively, based on the results of previous reports . MTV was defined as the summed volume of the voxels whose SUV was higher than the cutoff value in semiautomatically delineated VOI.…”

Section: Methodsmentioning

confidence: 99%

“…Recently, metabolic tumor burden, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which reflects both tumor volume and glycolysis, have been widely used and reported in FDG‐PET/CT studies . However, in most previous studies, metabolic tumor burden obtained from a single‐phase study has been used, and a few studies have applied such parameters calculated using a dual‐time‐point study …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of metabolic tumor burden calculated using dual‐time‐point 18F‐fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer

et al. 2018

View full text Add to dashboard Cite

Background: This study investigates the prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT in patients with locally advanced cancer. Methods: This study examines 42 patients (35 men and 7 women, 38-73 years old) with locally advanced oropharyngeal or hypopharyngeal cancer who had undergone FDG-PET/CT before receiving chemoradiotherapy. Maximum standardized uptake value (SUV max ), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for the early and delayed phases. Statistical analyses included receiver operating characteristic curve, univariate and multivariate analysis. Results: ΔSUV max , both phases of MTV 2.5 and TLG 2.5 , early TLG 40% , ΔTLG 2.5 , and ΔTLG 40% were significantly associated with progression-free survival (PFS). In multivariate analysis, early TLG 2.5 (P = .005) was an independent prognostic factor of PFS. Conclusion: Not the percent change but the value calculated in the early phase in several parameters using dual-time-point FDG-PET/CT is significantly associated with the outcomes of patients with locally advanced oropharyngeal or hypopharyngeal cancer.

show abstract

“…Two patient groups were established according to the results of the PET/MR therapeutic response evaluation and the clinical follow-up. Furthermore, patient subgroups were also set up, namely a complete remission (CR) group defined as patients with an absence of a viable primary tumor tissue and a non-complete remission (NCR) group defined as patients with any pernicious proliferations including partial response, stable disease, and progressive disease groups ( 24 , 25 ).…”

Section: Methodsmentioning

confidence: 99%

Predictive Value of Diffusion, Glucose Metabolism Parameters of PET/MR in Patients With Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy

Kedves¹,

Tóth²,

Emri³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Purpose: This study aims to evaluate the predictive value of the pretreatment, metabolic, and diffusion parameters of a primary tumor assessed with PET/MR on patient clinical outcomes. Methods: Retrospective evaluation was performed using PET/MR image data sets acquired using the single tracer injection dual imaging of 68 histologically proven head and neck cancer patients 4 weeks before receiving definitive chemoradiotherapy (CRT). PET/MR was performed before the CRT and 12 weeks after the CRT for response evaluation. Image data (PET and MRI diffusion-weighted imaging [DWI]) was used to specify the maximum standard uptake value, the peak lean body mass corrected, SUV max , the metabolic tumor volume, the total lesion glycolysis (SUV max , SUL peak , MTV, and TLG), and the mean apparent diffusion coefficient (ADC mean ) of the primary tumor. Based on the results of the therapeutic response evaluation, two patient subgroups were created: one with a viable tumor and another without. Metabolic and diffusion data, from the pretreatment PET/MR and the therapeutic response, were correlated using Spearman's correlation coefficient and Wilcoxon's test. Results: After completing the CRT, a viable residual tumor was detected in 36/68 (53%) cases, and 32/68 (47%) patients showed complete remission. However, no significant correlation was found between the pretreatment parameter, ADC mean ( p = 0.88), and the therapeutic success. The PET parameters, SUV max and SUL peak , MTV, and TLG ( p = 0.032, p = 0.01, p < 0.0001, p = 0.0004) were statistically significantly different between the two patient subgroups. Conclusion: This study found that MRI-based (ADC mean ) data from FDG PET/MR pretreatment could not be used to predict therapeutic response although the PET parameters SUV max , SUL peak , MTV, and TLG proved to be more useful; thus, their inclusion in risk stratification may also be of additional value.

show abstract

Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy

Abstract: TLG was found to be a good predictive factor for metastatic lymph node(s) prior to CRT treatment. After CRT treatment, FDG-PET was found to be highly specific and useful for negative screening.

Cited by 6 publications

References 30 publications

[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis

[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis

Prognostic value of metabolic tumor burden calculated using dual‐time‐point 18F‐fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer

Predictive Value of Diffusion, Glucose Metabolism Parameters of PET/MR in Patients With Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy

Contact Info

Product

Resources

About